Outlook Therapeutics names Kevin Lundquist CFO, Kenyon departs Sept 1

Outlook Therapeutics, Inc.

CFO Lawrence Kenyon to step down Sept 1, 2026; stays non-executive through Sept 30, 2026; leaves board by then.
Kevin Lundquist appointed CFO, Treasurer, principal financial/accounting officer effective Sept 1; previously CFO at CapsoVision (Nasdaq: CV).
Lundquist receives $450k base salary, 50% target bonus, and option for 500k shares vesting over 4 years.
Kenyon severance: 12 months base salary + $20k + full 2026 target bonus; 100% option acceleration; 12 months COBRA.
Board to shrink to eight directors upon Kenyon's board departure; transition not due to any accounting or policy disagreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.